References for Cytochrome P450 Drug Interaction Table: 2C19
These pages contain all the literature citations referenced in the Cytochrome P450 Drug Interaction Tables (both the extensive research-oriented table and the concise clinical table). Most of these citations are hyperlinks, which bring up the abstract in the NLM's PubMed database.
Click on the [ PubMed ] link after the drug name to perform a live MedLINE search of articles possibly related to that drug and Cytochrome P450.
Entries are organized by mode of activity (substrate, inhibitor, inducer) within specific isoform. You can quickly branch to a section by clicking on the appropriate link here:
1A2 | 2B6 | 2C8 | 2C19 | 2C9 | 2D6 | 2E1 | 3A457
Use Ctrl-F to find all or part of the name or word for which you are searching.
2C19 Itself:
PubMed
Isolation and Characterization of Human Liver Cytochrome
P450 2C19: correlation between 2C19 and S-mephenytoin
4'-hydroxylation.
Wrighton SA, Stevens JC, Becker GW and Vandenbranden M
Pubmed
Biochem Biophys 1993 Oct;306(1):240-245
amitriptyline:
PubMed
Five distinct human cytochromes mediate amitriptyline N-demethylation
in vitro: dominance of CYP 2C19 and 3A4.
Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS,
Shader RI
Clin Pharmacol. 1998 Feb; 38(2): 112-121
Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed
human cytochrome P450 enzymes.
Olesen OV, Linnet K
Pharmacology.
1997 Nov; 55(5): 235-243
Cytochromes P450 mediating the N-demethylation of amitriptyline.
Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT
Br
J Clin Pharmacol. 1997 Feb; 43(2): 137-144
chloramphenicol: PubMed
Chloramphenicol Is a Potent Inhibitor of Cytochrome P450 Isoforms CYP2C19 and CYP3A4 in Human Liver Microsomes.
Park JY, Kim KA, Kim SL.
Antimicrob Agents Chemother. 2003 Nov;47(11):3464-9.
citalopram:
PubMed
Personal communication with Dr. Terence Ketter about citalopram on March
29, 1995.
Ketter, T.A
Flockhart, D.A. 1995
clomipramine:
PubMed
Pharmacogenetics of antidepressants: clinical aspects.
Bertilsson L, Dahl ML, Tybring G
Acta
Psychiatr Scand Suppl 1997;391:14-21
cyclophosphamide:
PubMed
Identification of the polymorphically
expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as
low-Km catalysts of cyclophosphamide and ifosfamide
activation.
Chang TKH, Yu L, Goldstein JA, Waxman DJ
Pharmacogenetics
1997;7:211-221
diazepam:
PubMed
Cytochrome P450 mediated metabolism of diazepam
in human and rat: involvement of human CYP2C in N-demethylation in the substrate
concentration-dependent manner.
Yasumori T, Nagata K, Yang SK, Chen L-S, Murayama N, Yamazoe Y, Kato R
Pharmacogenetics
1993;3:291-301
E-3810:
PubMed
Comparison of the kinetic disposition and metabolism
of E3810, a new proton pump inhibitor, and omeprazole in relation to
S-mephenytoin 4'-hydroxylation status.
Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba
K, Ishizaki T
Clin
Pharmacol Ther 1995 Aug;58(2):143-154
escitalopram:
PubMed
hexobarbital:
PubMed
Stereoselective disposition of hexobarbital and its metabolites: relationship
to the S-mephenytoin polymorphism in Caucasian and Chinese subjects.
Adedoyin A, Prakash C, O'Shea D, Blair IA, Wilkinson GR
Pharmacogenetics.
1994 Feb; 4(1): 27-38
Polymorphism in stereoselective hydroxylations of mephenytoin and hexobarbital
by Japanese liver samples in relation to cytochrome P-450 human-2
(IIC9).
Kato R, Yamazoe Y, Yasumori T
Xenobiotica.
1992 Sep; 22(9-10): 1083-1092. Review
Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers
in relation to hepatic P-450 human-2.
Yasumori T, Murayama N, Yamazoe Y, Kato R
Clin
Pharmacol Ther. 1990 Mar; 47(3): 313-322
Oxidative metabolism of hexobarbital in human liver: relationship to
polymorphic S-mephenytoin 4-hydroxylation.
Knodell RG, Dubey RK, Wilkinson GR, Guengerich FP
J
Pharmacol Exp Ther. 1988 Jun; 245(3): 845-849
imipramine N-deME:
PubMed
Reappraisal of human CYP isoforms involved in imipramine N-demethylation
and 2-hydroxylation: a study using microsomes obtained from putative extensive
and poor metabolizers of S-mephenytoin and eleven recombinant human
CYPs.
Koyama E, Chiba K, Tani M, Ishizaki T
J
Pharmacol Exp Ther. 1997 Jun; 281(3): 1199-1210.
Geographical/interracial differences in polymorphic drug oxidation. Current
state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
Bertilsson L.
Clin
Pharmacokinet. 1995 Sep; 29(3): 192-209. Review.
indomethacin:
PubMed
Human cytochrome P4502C metabolism.
Weaver RJ, Webster D, Melvin WT, Dickins M and Burke MD
Br J Clin Pharmacol 1993 April;36(2):167P
lansoprazole:
PubMed
Metabolic disposition of lansoprazole in relation to the S-mephenytoin
4'-hydroxylation phenotype status.
Sohn DR, Kwon JT, Kim HK, Ishizaki T
Clin
Pharmacol Ther 1997 May;61(5):574-582
S-mephenytoin:
PubMed
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new
oxidative drug metabolism polymorphism.
Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA
Clin
Pharmacol Ther, 1984 Dec; 36(6):773-780
R-mephobarbital:
PubMed
Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin
hydroxylation.
Kupfer A, Branch RA
Clin
Pharmacol Ther, 1985 Oct; 38(4):414-418
moclobemide:
PubMed
Moclobemide: a substrate of CYP2C19 and an inhibitor
of CYP2C19, CYP2D6 and CYP1A2: A panel study.
Gram LF, Guentert TW, Grange S, Vistisen K, Brøsen K
Clin
Pharmacol Ther 1995;57(6):670-677
nelfinavir:
PubMed
Characterization of the selectivity and mechanism of human cytochrome
P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir
mesylate.
Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, Lee CA
Drug
Metab Dispos 1998 Jul;26(7):609-16
nilutamide:
PubMed
Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats
and in human liver microsomes.
Horsmans Y, Lannes D, Larrey D, Tinel M, Letteron P, Loeper J, Pessayre D
Xenobiotica
1991 Dec;21(12):1559-1570
omeprazole:
PubMed
Effect of omeprazole on diazepam plasma levels in slow versus normal rapid
metabolizers of omeprazole.
Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P
Clin
Pharmacol Ther 1990;47(1):79-85
Oxcarbazepine:
PubMed
Spotlight on oxcarbazepine in epilepsy.
Bang LM, Goa KL.
CNS Drugs. 2004;18(1):57-61.
pantoprazole:
PubMed
Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation
to S-mephenytoin 4'-hydroxylation phenotype and genotype.
Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, Hakusui
H, Yamamori S, Ishizaki T
Clin
Pharmacol Ther 1997 Dec;62(6):619-628
phenytoin:
PubMed
Role of S-mephenytoin hydroxylase in the metabolism of phenytoin.
Bajpai M, Roskos LK, Shen DD, Trager WF, Levy RH
Pharm Res 1994, 11(Suppl):S348
phenobarbitone:
Pubmed
CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese
patients with epilepsy: analysis by population pharmacokinetics.
Mamiya K, Hadama A, Yukawa E, Ieiri I, Otsubo K, Ninomiya H, Tashiro N, Higuchi
S
Eur J Clin Pharmacol 2000, 55:821-825
primidone:
PubMed
progesterone:
PubMed
Progesterone and testosterone hydroxylation by CYP 2C19, 2C9 and 3A4 in
human liver microsomes.
Yamazaki H, Shimada T
Arch
Biochem Biophys 1997;346(1):161-169
proguanil:
PubMed
Metabolic Disposition of proguanil in extensive and poor metabolizers
of S-mephenytoin 4'-hydroxylation recruited from an Indonesian
population.
Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T
Br
J Clin Pharmacol 1995;39(3):297-303
In vitro proguanil activation to cycloguanil by human liver microsomes
is mediated by CYP3A isoforms as well as S-mephenytoin hydroxylase.
Birkett DJ, Rees D, Andersson T, Gonzalex FJ, Miners JO, Veronese ME
Br
J Clin Pharmacol 1994;37:413-420
The activation of the biguanide anti-malarial proguanil co-segregates
with the mephenytoin oxidation polymorphism - a panel study.
Ward SA, Helsby NA, Skjelbo E, Brøsen K, Gram LF, Breckenridge AM
Br
J Clin Pharmacol 1991;31:689-692
Relation between chloroguanide bioavtivation to cycloguanil and the
genetically determined metabolism of mephenytoin in humans.
Funck-Brentano C, Bosco O, Jacqz-Aigrain E, KeunjiN a, Jaillon P
Clin
Pharmacol Ther 1992;51(5):507-512
propranolol:
PubMed
Not in vitro. Propranolol oxidation by human liver microsomes-- use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity.
Otton SV, Gillam EM, Lennard MS, Tucker GT, Woods HF
Br J Clin Pharmacol 1990 Nov;30(5):751-760
rabeprazole: Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S.
Clin Pharmacol Ther. 2006 Jan;79(1):144-52.
R-warfarin:
PubMed
Correlation of human cytochrome P450 2C substrate specificities with primary
structure: warfarin as a probe.
Kaminsky LS, de Morais SM, Faletto MB, Dunbar DA, Goldstein JA
Mol
Pharmacol 1993;43:234-239
teniposide:
PubMed
| E3810 |
[ PubMed ] |
| Article | Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status. |
| Authors | Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. |
| Link to Abstract | Clin Pharmacol Ther 1995 Aug;58(2):143-154.
|
| Article | Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. |
| Authors | Ishizaki T, Chiba K, Manabe K, Koyama E, Hayashi M, Yasuda S, Horai Y, Tomono Y, Yamato C, Toyoki T. |
| Link to Abstract | Clin Pharmacol Ther. 1995 Aug;58(2):155-64. |
| FLUOXETINE |
[ PubMed ] |
| Article | Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. |
| Authors | McGinnity DF, Berry AJ, Kenny JR, Grime K, Riley RJ. |
| Link to Abstract | Drug Metab Dispos. 2006 Aug;34(8):1291-300.
|
| Article | Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. |
| Authors | Harvey AT, Preskorn SH. |
| Link to Abstract | J Clin Psychopharmacol. 2001 Apr;21(2):161-6.
|
| Article | Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. |
| Authors | Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. |
| Link to Abstract | Eur J Clin Pharmacol. 1996;51(1):73-8.
|
| Article | The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes. |
| Authors | Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y. |
| Link to Abstract | Br J Clin Pharmacol. 1995 Nov;40(5):481-5.
|
| Info | www.rxlist.com |
| FLUVOXAMINE |
[ PubMed ] |
| Article | Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. |
| Authors | von Richter O, Lahu G, Huennemeyer A, Herzog R, Zech K, Hermann R. |
| Link to Abstract | Clin Pharmacokinet. 2007;46(7):613-22.
|
| Article | Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. |
| Authors | Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S, Tateishi T. |
| Link to Abstract | Br J Clin Pharmacol. 2004 Apr;57(4):487-94.
|
| Article | Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles. |
| Authors | Suzuki Y, Shioiri T, Muratake T, Kawashima Y, Sato S, Hagiwara M, Inoue Y, Shimoda K, Someya T. |
| Link to Abstract | Eur J Clin Pharmacol. 2003 Apr;58(12):829-33.
|
| Info | www.rxlist.com |
| KETOCONAZOLE |
[ PubMed ] |
| Article | Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. |
| Authors | Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JC, Patten CJ, Dehal SS, Crespi CL. |
| Link to Abstract | Drug Metab Dispos. 2004 Jan;32(1):105-12.
|
| Article | In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. |
| Authors | Emoto C, Murase S, Sawada Y, Jones BC, Iwasaki K. |
| Link to Abstract | Drug Metab Pharmacokinet. 2003;18(5):287-95.
|
| Info | www.rxlist.com |
| » LANSOPRAZOLE |
[ PubMed ] |
| Article | Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. |
| Authors | Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. |
| Link to Abstract | Eur J Clin Pharmacol 1985;28:257-261.
|
| Article | Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. |
| Authors | Li XQ, Andersson TB, Ahlström M, Weidolf L. |
| Link to Abstract | Drug Metab Dispos. 2004 Aug;32(8):821-7.
|
| Article | Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. |
| Authors | Liu KH, Kim MJ, Shon JH, Moon YS, Seol SY, Kang W, Cha IJ, Shin JG. |
| Link to Abstract | Xenobiotica. 2005 Jan;35(1):27-38.
|
| Info | www.rxlist.com |
| » PANTOPRAZOLE |
[ PubMed ] |
| Article | Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype. |
| Authors | Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, Ryokawa Y, Hakusui H, Yamamori S, Ishizaki T. |
| Link to Abstract | Clin Pharmacol Ther 1997 Dec;62(6):619-628.
|
| Info | www.rxlist.com |
| » RABEPRAZOLE |
[ PubMed ] |
| Article | Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. |
| Authors | Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S. |
| Link to Abstract | Clin Pharmacol Ther. 2006 Jan;79(1):144-52.
|
| Article | Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. |
| Authors | Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T. |
| Link to Abstract | Br J Clin Pharmacol. 2006 Mar;61(3):309-14.
|
| Info | www.rxlist.com |
| Info | www.rxlist.com |
| » TICLOPIDINE |
[ PubMed ] |
| Article | Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. |
| Authors | Ieiri I, Kimura M, Irie S, Urae A, Otsubo K, Ishizaki T. |
| Link to Abstract | Pharmacogenet Genomics. 2005 Dec;15(12):851-9.
|
| Article | Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. |
| Authors | Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M, Kobayashi S. |
| Link to Abstract | Br J Clin Pharmacol. 1999 Apr;47(4):454-7.
|
| Article | Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. |
| Authors | Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, Mansuy D. |
| Link to Abstract | Biochemistry. 2001 Oct 9;40(40):12112-22.
|
| Article | Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. |
| Authors | Donahue SR, Flockhart DA, Abernethy DR, Ko JW. |
| Link to Abstract | Clin Pharmacol Ther. 1997 Nov;62(5):572-7.
|
| Info | www.rxlist.com |
| » TOPIRAMATE |
[ PubMed ] |
| Article | Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. |
| Authors | Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin CR, Doose DR, Gisclon LG, Bialer M. |
| Link to Abstract | Epilepsia. 2002 Jul;43(7):691-6.
|
| Info | www.rxlist.com |
carbamazepine:
PubMed
norethindrone:
PubMed
NOT pentobarbital:
PubMed
Influence of enzyme induction and inhibition on
the oxidation of nifedipine, mephenytoin and antipyrine in humans as assessed
by a "cocktail" study design.
Schellens JHM, van der Wart JHF, Brugman M, Breimer DD
J
Pharmac Exp Ther 1989;249(2):638-645
prednisone:
PubMed
Influence of corticosteroid on hexobarbital and
tolbutamide disposition.
Breimer DD, Zilly W, Richter E
Clin
Pharmacol Ther 1978 Aug;24(2):208-212
rifampin:
PubMed
Induction of polymorphic 4'-hydroxylation of
S-mephenytoin by rifampicin.
Zhou HH, Anthony LB, Wood AJJ, Wilkinson GR
Br
J Clin Pharmacol 1990;30:471-475
|